# Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.

> **NCT01233843** · PHASE3 · COMPLETED · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 370 (actual)

## Conditions studied

- Squamous Cell Head and Neck Carcinoma

## Interventions

- **DRUG:** carboplatin
- **DRUG:** 5 fluorouracil
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT01233843
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-18
- **Primary completion:** 2018-11-06
- **Final completion:** 2018-11-06
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2019-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233843, "Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01233843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*